Recent advances of IDH1 mutant inhibitor in cancer therapy

Isocitrate dehydrogenase (IDH) is the key metabolic enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG). Two main types of IDH1 and IDH2 are present in humans. In recent years, mutations in IDH have been observed in several tumors, including glioma, acute myeloid leukemia, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Wangqi, Zhang, Weitong, Wang, Yifan, Jin, Ruyi, Wang, Yuwei, Guo, Hui, Tang, Yuping, Yao, Xiaojun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449373/
https://www.ncbi.nlm.nih.gov/pubmed/36091829
http://dx.doi.org/10.3389/fphar.2022.982424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9449373/
https://www.ncbi.nlm.nih.gov/pubmed/36091829
http://dx.doi.org/10.3389/fphar.2022.982424

Ejemplares similares